Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12729
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, Annette Men
dc.contributor.authorCandiloro, Ida Lmen
dc.contributor.authorWong, Nicholasen
dc.contributor.authorCollins, Marnieen
dc.contributor.authorDo, Hongdoen
dc.contributor.authorTakano, Elena Aen
dc.contributor.authorAngel, Christopheren
dc.contributor.authorYoung, Richard Jen
dc.contributor.authorCorry, Juneen
dc.contributor.authorWiesenfeld, Daviden
dc.contributor.authorKleid, Stephenen
dc.contributor.authorSigston, Elizabethen
dc.contributor.authorLyons, Bernarden
dc.contributor.authorRischin, Dannyen
dc.contributor.authorSolomon, Benjamin Jen
dc.contributor.authorDobrovic, Alexanderen
dc.date.accessioned2015-05-16T02:27:41Z
dc.date.available2015-05-16T02:27:41Z
dc.date.issued2014-12-09en
dc.identifier.citationClinical Epigenetics 2014; 6(1): 22en
dc.identifier.govdoc25859283en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12729en
dc.description.abstractDNA hypermethylation is reported as a frequent event and prognostic marker in head and neck squamous cell carcinomas (HNSCC). Methylation has been commonly assessed with non-quantitative methodologies, such as methylation-specific PCR (MSP). We investigated previously reported hypermethylated genes with quantitative methodology in oral tongue squamous cell carcinomas (OTSCC).The methylation status of 12 genes in 115 OTSCC samples was assessed by one or more of three quantitative analyses: methylation sensitive high resolution melting (MS-HRM), sensitive-melting analysis after real time-methylation specific PCR (SMART-MSP), and bisulfite pyrosequencing. In contrast to much of the literature, either no or infrequent locus-specific methylation was identified by MS-HRM for DAPK1, RASSF1A, MGMT, MLH1, APC, CDH1, CDH13, BRCA1, ERCC1, and ATM. The most frequently methylated loci were RUNX3 (18/108 methylated) and ABO (22/107 methylated). Interrogation of the Cancer Genome Atlas (TCGA) HNSCC cohort confirmed the frequency of significant methylation for the loci investigated. Heterogeneous methylation of RUNX3 (18/108) and ABO (22/107) detected by MS-HRM, conferred significantly worse survival (P = 0.01, and P = 0.03). However, following quantification of methylation levels using pyrosequencing, only four tumors had significant quantities (>15%) of RUNX3 methylation which correlated with a worse patient outcome (P <0.001), while the prognostic significance of ABO hypermethylation was lost. RUNX3 methylation was not prognostic for the TCGA cohort (P = 0.76).We demonstrated the critical need for quantification of methylation levels and its impact on correlative analyses. In OTSCC, we found little evidence of significant or frequent hypermethylation of many loci reported to be commonly methylated. It is likely that previous reports have overestimated the frequency of significant methylation events as a consequence of the use of non-quantitative methodology.en
dc.language.isoenen
dc.subject.otherHead and neck canceren
dc.subject.otherMethylationen
dc.subject.otherQuantitativeen
dc.subject.otherRUNX3en
dc.subject.otherTongueen
dc.titleQuantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical epigeneticsen
dc.identifier.affiliationTranslational Genomics and Epigenomics Laboratory, Ludwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Health, 145-163 Studley Road, Heidelberg, Victoria 3084 Australia ; Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australia ; School of Cancer Medicine, La Trobe University, Bundoora, Victoria 3084 Australiaen
dc.identifier.affiliationThe University of Melbourne, Parkville, Victoria 3010 Australia ; Translational Genomics and Epigenomics Laboratory, Ludwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Health, 145-163 Studley Road, Heidelberg, Victoria 3084 Australiaen
dc.identifier.affiliationDepartment of Surgery, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168 Australiaen
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australiaen
dc.identifier.affiliationDepartment of Surgery, Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria 3050 Australiaen
dc.identifier.affiliationThe University of Melbourne, Parkville, Victoria 3010 Australia ; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australiaen
dc.identifier.affiliationResearch Division, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australiaen
dc.identifier.affiliationDepartment of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australiaen
dc.identifier.affiliationResearch Division, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australia ; Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australiaen
dc.identifier.affiliationDepartment of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australiaen
dc.identifier.affiliationResearch Division, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australia ; Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3010 Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australia ; The University of Melbourne, Parkville, Victoria 3010 Australia ; Research Division, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australia ; The University of Melbourne, Parkville, Victoria 3010 Australiaen
dc.identifier.affiliationTranslational Genomics and Epigenomics Laboratory, Ludwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Health, 145-163 Studley Road, Heidelberg, Victoria 3084 Australia ; Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A'Beckett Street, Melbourne, Victoria 8006 Australia ; Department of Pathology, The University of Melbourne, Parkville, Victoria 3010 Australia ; School of Cancer Medicine, La Trobe University, Bundoora, Victoria 3084 Australiaen
dc.identifier.affiliationDepartment of Surgery, St Vincent's Hospital, PO Box 2900, Fitzroy, Victoria 3065 Australiaen
dc.identifier.doi10.1186/1868-7083-6-22en
dc.description.pages22en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25859283en
dc.type.austinJournal Articleen
local.name.researcherDobrovic, Alexander
item.languageiso639-1en-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
25859283.pdf810.84 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

10
checked on May 13, 2024

Download(s)

74
checked on May 13, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.